US Stock Market Move | Eikon Therapeutics (EIKN.US) debuts on Nasdaq, opens with over 5% decline.
Eikon Therapeutics debuts on NASDAQ, opening down over 5% at $17.05.
On Thursday, Eikon Therapeutics (EIKN.US) debuted on the Nasdaq, opening down over 5% at $17.05, below its IPO price of $18. Founded in 2019 by Nobel laureates Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian, Eikon Therapeutics is currently focused on developing a pipeline of experimental cancer therapies. The company's lead candidate drug, EIK1001, is progressing rapidly and is in mid-to-late stage clinical trials for skin cancer in collaboration with Merck & Co., Inc. (MRK.US). The mid-term analysis data from this study is expected to be released in the second half of 2026.
Related Articles
Zhejiang Chenfeng Technology (603685.SH): Hong Kong Ji Fei plans to transfer its 5.98% stake in the company to Leng Wenlong.
Apple Flavor & Fragrance Group (603020.SH) signs an intention agreement to acquire the equity of Noah Saint Nuo (Taicang) Biotechnology Co., Ltd.
US Stock Market Move | Bob's Discount Furniture (BOBS.US) enters the US stock market, opening with a more than 10% increase.
Zhejiang Chenfeng Technology (603685.SH): Hong Kong Ji Fei plans to transfer its 5.98% stake in the company to Leng Wenlong.
Apple Flavor & Fragrance Group (603020.SH) signs an intention agreement to acquire the equity of Noah Saint Nuo (Taicang) Biotechnology Co., Ltd.
US Stock Market Move | Bob's Discount Furniture (BOBS.US) enters the US stock market, opening with a more than 10% increase.
